Cediranib
Recurrent Vulvar Cancer
Steven Waggoner, MDSmall moleculePhase 1Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Recurrent Vulvar Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Case Comprehensive Cancer Center | Phase 1 | CCC |
Triapine National Cancer Institute (NCI) | Phase 1 | CC |
Recombinant Interleukin-12 National Cancer Institute (NCI) | Phase 1 | CC |
TRASTUZUMAB National Cancer Institute (NCI) | Phase 1 | CC |
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Institute (NCI) | Phase 1 | CC |
Abi-007 National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →